CN114002133A - 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 - Google Patents
血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 Download PDFInfo
- Publication number
- CN114002133A CN114002133A CN202111238363.5A CN202111238363A CN114002133A CN 114002133 A CN114002133 A CN 114002133A CN 202111238363 A CN202111238363 A CN 202111238363A CN 114002133 A CN114002133 A CN 114002133A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- exosomes
- serum
- positive
- flow cytometry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 79
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 47
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 47
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 39
- 210000002966 serum Anatomy 0.000 title claims abstract description 38
- 230000035945 sensitivity Effects 0.000 title claims abstract description 25
- 239000003550 marker Substances 0.000 title claims abstract description 7
- 238000000684 flow cytometry Methods 0.000 claims abstract description 26
- 239000011324 bead Substances 0.000 claims abstract description 22
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 238000004458 analytical method Methods 0.000 claims abstract description 6
- 238000012512 characterization method Methods 0.000 claims abstract description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 49
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 49
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 8
- 102000004121 Annexin A5 Human genes 0.000 claims description 6
- 108090000672 Annexin A5 Proteins 0.000 claims description 6
- 239000011325 microbead Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 17
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 102100023962 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 108010077613 phosphatidylserine receptor Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
- G01N15/1436—Optical arrangements the optical arrangement forming an integrated apparatus with the sample container, e.g. a flow cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
- G01N2015/144—Imaging characterised by its optical setup
- G01N2015/1445—Three-dimensional imaging, imaging in different image planes, e.g. under different angles or at different depths, e.g. by a relative motion of sample and detector, for instance by tomography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111238363.5A CN114002133B (zh) | 2021-10-25 | 2021-10-25 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111238363.5A CN114002133B (zh) | 2021-10-25 | 2021-10-25 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114002133A true CN114002133A (zh) | 2022-02-01 |
CN114002133B CN114002133B (zh) | 2023-01-24 |
Family
ID=79923659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111238363.5A Active CN114002133B (zh) | 2021-10-25 | 2021-10-25 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114002133B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113024673A (zh) * | 2020-07-21 | 2021-06-25 | 上海交通大学 | 磷脂酰丝氨酸多肽配体修饰的二氧化硅微球 |
CN117741153A (zh) * | 2023-11-07 | 2024-03-22 | 南京联笃生物科技有限公司 | 一种用于多癌种早期筛查、诊断和/或监测的生物标志物及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104109209A (zh) * | 2005-01-24 | 2014-10-22 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的Fc融合构建体及其治疗用途 |
CA2988771A1 (en) * | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Texas System | Diagnostic test for early stage cancer |
CN107488738A (zh) * | 2017-10-12 | 2017-12-19 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标志物 |
WO2020160108A1 (en) * | 2019-01-30 | 2020-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Lipid biomarkers for cancer screening and monitoring |
CN112760380A (zh) * | 2021-02-04 | 2021-05-07 | 山东大学 | 评估三阴性乳腺癌对新辅助化疗药物敏感性和/或预后的标志物及其应用 |
-
2021
- 2021-10-25 CN CN202111238363.5A patent/CN114002133B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104109209A (zh) * | 2005-01-24 | 2014-10-22 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的Fc融合构建体及其治疗用途 |
CA2988771A1 (en) * | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Texas System | Diagnostic test for early stage cancer |
CN107488738A (zh) * | 2017-10-12 | 2017-12-19 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标志物 |
WO2020160108A1 (en) * | 2019-01-30 | 2020-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Lipid biomarkers for cancer screening and monitoring |
CN112760380A (zh) * | 2021-02-04 | 2021-05-07 | 山东大学 | 评估三阴性乳腺癌对新辅助化疗药物敏感性和/或预后的标志物及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113024673A (zh) * | 2020-07-21 | 2021-06-25 | 上海交通大学 | 磷脂酰丝氨酸多肽配体修饰的二氧化硅微球 |
CN117741153A (zh) * | 2023-11-07 | 2024-03-22 | 南京联笃生物科技有限公司 | 一种用于多癌种早期筛查、诊断和/或监测的生物标志物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114002133B (zh) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114002133B (zh) | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 | |
Jørgensen et al. | Extracellular Vesicle (EV) Array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping | |
Notarangelo et al. | Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood | |
Mathivanan et al. | Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature | |
Xu et al. | Recent progress of exosome isolation and peptide recognition-guided strategies for exosome research | |
US20160370265A1 (en) | Method for isolating exosomes | |
Guo et al. | based ITP technology: An application to specific cancer-derived exosome detection and analysis | |
CN108802389B (zh) | 一种用于早期非小细胞肺癌诊断的试剂盒 | |
EP3577463B1 (en) | Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples | |
Ströhle et al. | Affinity-based isolation of extracellular vesicles and the effects on downstream molecular analysis | |
US20120295286A1 (en) | Methods for the Diagnosis, Prognosis and Monitoring of Cancer Therapy Using BP1 | |
WO2014040483A1 (zh) | 一种获取循环肿瘤单细胞的方法 | |
CN104807996A (zh) | 细胞表面标志分子用于检测肝癌循环肿瘤细胞的用途 | |
JP7444386B2 (ja) | ヒト尿からのマイクロベシクルの分離方法及び分析方法 | |
Benecke et al. | Isolation and analysis of tumor‑derived extracellular vesicles from head and neck squamous cell carcinoma plasma by galectin‑based glycan recognition particles | |
JP7376021B2 (ja) | ヒト血液からのマイクロベシクルの分離方法及び分析方法 | |
Hadifar et al. | Exosomes in tuberculosis: Still terra incognita? | |
Wang et al. | A light-activated magnetic bead strategy utilized in spatio-temporal controllable exosomes isolation | |
Ngo et al. | Improving SERS biosensors for the analysis of ovarian cancer-derived small extracellular vesicles | |
US20180203013A1 (en) | Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients | |
Yu et al. | Exosomal miRNAs from neutrophils act as accurate biomarkers for gastric cancer diagnosis | |
Feng et al. | Simultaneous detection of two extracellular vesicle subpopulations in saliva assisting tumor T staging of oral squamous cell carcinoma | |
JP2013185921A (ja) | 肺腺扁平上皮癌の腫瘍マーカー及び診断キット | |
Brahmer et al. | Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles | |
Nazarova et al. | Colorectal cancer diagnostics via detection of tissue-specific extracellular nano-vesicles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zeng Ke Inventor after: Yang Rong Inventor after: Liang Hongwei Inventor after: Jiang Xinli Inventor after: Li Jianfeng Inventor after: Qu Shuang Inventor before: Yang Rong Inventor before: Li Jianfeng Inventor before: Jiang Xinli Inventor before: Zeng Ke Inventor before: Liang Hongwei Inventor before: Qu Shuang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |